Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer
February 01 2021 - 7:30AM
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of Haduvio™ (nalbuphine ER) to treat serious
neurologically mediated conditions, today announced the appointment
of William Forbes, Pharm.D., as Chief Development Officer. Dr.
Forbes will join Trevi’s senior management team and be responsible
for leading the clinical development of Haduvio which is in
late-stage clinical trials in its two lead indications.
“I am happy to welcome Bill to our executive leadership team,”
said Jennifer L. Good, President and Chief Executive Officer of
Trevi. “Bill has a proven track record of success in developing and
managing highly effective product development teams and progressing
products through all phases of clinical development and regulatory
milestones, including multiple approvals. Bill’s extensive
experience in pharmaceutical product development will be extremely
valuable as we complete enrollment and report top-line data from
our Phase 2b/3 trial for chronic pruritus in patients with prurigo
nodularis and our Phase 2 trial for chronic cough in patients with
IPF and prepare for the next steps in development for both of these
programs.”
Dr. Forbes joins Trevi with over 30 years of experience in
pharmaceutical product development. Before joining Trevi, he served
as Founder, President and CEO of Vivelix Pharmaceuticals. Prior to
Vivelix, Dr. Forbes held multiple senior leadership positions
throughout his career, including Chief Development Officer for
Salix Pharmaceuticals where he was responsible for the development
of Xifaxan (rifaximin) in multiple indications. Dr. Forbes’
contributions at Salix were instrumental in guiding 12 FDA
approvals. He holds a Pharm.D. from Creighton University.
“This is an exciting time to join Trevi with two late-stage
development programs of Haduvio ongoing which could help to meet
the needs’ of patients suffering from serious conditions with no
approved therapies,” said Dr. Forbes. “I am impressed with Trevi’s
highly skilled professionals and look forward to working with the
team to achieve key near-term product development goals this
year.”
About Trevi Therapeutics, Inc.Trevi
Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of Haduvio
to treat serious neurologically mediated conditions. Trevi is
currently developing Haduvio for the treatment of chronic pruritus,
chronic cough in patients with idiopathic pulmonary fibrosis (IPF)
and levodopa-induced dyskinesia (LID) in patients with Parkinson’s
disease. These conditions share a common pathophysiology that is
mediated through opioid receptors in the central and peripheral
nervous systems. Trevi is currently conducting a Phase 2b/3
clinical trial of Haduvio, referred to as the PRISM trial, in
patients with severe pruritus associated with prurigo nodularis and
a Phase 2 trial for chronic cough in patients with IPF.
Founded in 2011, Trevi Therapeutics is headquartered
in New Haven, CT.
About HADUVIOHaduvio is an oral extended
release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that has been
approved and marketed as an injectable for pain indications for
more than 20 years in the United States and Europe. The ĸ- and
µ-opioid receptors are known to be critical mediators of itch,
cough and certain movement disorders. Nalbuphine’s mechanism of
action also mitigates the risk of abuse associated with µ-opioid
agonists because it antagonizes, or blocks, µ-opioid receptors.
Nalbuphine is currently the only opioid approved for marketing that
is not classified as a controlled substance in the United States
and most of Europe. Trevi intends to propose Haduvio as the trade
name for the nalbuphine ER investigational product. Haduvio is an
investigational drug product and its safety and efficacy have not
been fully evaluated by any regulatory authority.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties and actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not
limited to, statements regarding the expected timing of enrollment
and for reporting top-line data from, Trevi’s Phase 2b/3 PRISM
trial of Haduvio in patients with prurigo nodularis; Trevi’s
business plans and objectives, including future plans or
expectations for Trevi’s product candidates; and other statements
containing the words “believes,” “anticipates,” “plans,” “expects,”
and similar expressions. Risks that contribute to the uncertain
nature of the forward-looking statements include: uncertainties
regarding the success, cost and timing of Trevi’s product candidate
development activities and ongoing and planned clinical trials;
uncertainties regarding the scope, timing and severity of the
COVID-19 pandemic, the impact of the COVID-19 pandemic on Trevi’s
clinical operations and actions taken in response to the pandemic;
uncertainties regarding Trevi’s ability to execute on its strategy;
the risk that positive results from a clinical trial may not
necessarily be predictive of the results of future or ongoing
clinical trials; potential regulatory developments in the
United States and foreign countries; uncertainties inherent in
estimating Trevi’s cash runway, future expenses and other financial
results; as well as other risks and uncertainties set forth in the
quarterly report on Form 10-Q for the quarter ended June 30,
2020 filed with the Securities and Exchange
Commission and in subsequent filings with the Securities
and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Trevi undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor ContactChris Seiter, Chief Financial
OfficerTrevi Therapeutics,
Inc.203-304-2499chris.seiter@trevitherapeutics.com
Media Contact Rosalia
Scampoli914-815-1465rscampoli@marketcompr.com
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024